| abstract |
REFERS TO COMPOUNDS DERIVED FROM BICYCLIC OXAZOLIDINONE FUSED FROM FORMULA (I) WHERE R1 IS H, ALKYL (C1-C5), HALOGEN, AMONG OTHERS; x IS 0 O 1; THE DISCONTINUED LINES REPRESENT AN OPTIONAL DOUBLE LINK; D1 IS N O CR2; D2 IS NO CR3; D3 IS N OR CR4, WHERE R2, R3 AND R4 ARE EACH H, ALKYL (C1-C5), O-ALKYL (C1-C5), ALKENYL (C2-C5), AMONG OTHERS; R5 IS ALKYL (C1-C5), ALKYNYL (C2-C5), HALOGEN, AMONG OTHERS; A1 IS PHENYL, CYCLOALKYL (C3-C8), AMONG OTHERS; A2 IS PHENYL, AMONG OTHERS; a IS FROM 0 TO 3. THE PREFERRED COMPOUNDS ARE: 3- [2 '- {(1R, 5S, 7aS) -1- [3,5-BIS (TRIFLUORomethyl) PHENYL] -3-OXOTETRAHYDRO-1H-PIRROLO [1, 2-c] [1,3] OXAZOLE-5-IL} -6-METOXY-4 '- (TRIFLUORomethyl) BIPHENYL-3-IL] METHYL PROPANOATE; ACID 3- [2 '- {(1R, 5S, 7aS) -1- [3,5-BIS (TRIFLUORomethyl) PHENYL] -3-OXOTETRAHYDRO-1H-PYRROLO [1,2-c] [1,3] OXAZOLE -5-IL} -6-METOXY-4 '- (TRIFLUORomethyl) BIPHENYL-3-IL] PROPANOIC; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN (CETP), BEING USEFUL IN THE TREATMENT OF DYSLIPIDEMIA, ATHEROSCLEROSIS |